Prostate Cancer LAI
Prostate Cancer
ApprovedActive
Key Facts
About Tolmar
Tolmar is a private, commercial-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of long-acting injectable drugs. Founded in 2002, it has built a portfolio of approved products sold in over 89 countries, primarily in therapeutic areas like prostate cancer, central precocious puberty, and testosterone replacement therapy. The company operates with a fully integrated model, controlling R&D, manufacturing in Colorado, and sales, which allows for a direct path to market and reliable supply. With over 1,100 employees, Tolmar leverages over 30 years of experience in long-acting injectables to differentiate itself and pursue partnerships for further growth.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |